Clin Assoc Prof Ng Kok Pin

Assoc Prof Ng Kok Pin is a Senior Consultant at the Department of Neurology, National Neuroscience Institute. He is the Chief Data and Digital Officer (CDDO), Director for Artificial Intelligence (AI) and Data Science (Neuroscience ACP), Head, Clinical Research Programs & Head, AI & Data Science Platform, and the Service Chief at NNI@TTSH for the SingHealth Duke-NUS Memory and Cognitive Disorder Centre.

Assoc Prof Ng specialises in neurocognitive disorders and his research focus on the identification of clinical markers such as cognitive, behavioral and genomic factors that predict cognitive decline using platforms such as neuroimaging (MRI and PET imaging), blood biomarkers, and MedTech/AI. He is an innovator under the SingHealth Duke-NUS AMII Healthcare Innovation & Transformation Fellowship and received the SingHealth GCEO Outstanding Researcher Award in 2025.

Assoc Prof Ng holds academic appointments at the Duke-NUS Medical School, Singapore, Yong Loo Lin School of Medicine, Singapore and Lee Kong Chian School of Medicine, Singapore. He is also a Board Member for the Chapter of Neurologists, Academy of Medicine, Singapore.

• MCI (NUS), 2015
• MRCP (UK), 2011
• MBBS National University of Singapore, 2006

• Senior Consultant, Department of Neurology, National Neuroscience Institute
• Chief Data and Digital Officer, National Neuroscience Institute
• Director for Artificial Intelligence (AI) and Data Science - Neuroscience ACP
• Head, Clinical Research Programs & Head, AI & Data Science Platform, National Neuroscience Institute
• Research Informatics Lead (EPIC), Office of Deputy Group Chief Medical Informatics Officer (Research), SingHealth
• Clinical Associate Professor – Duke-NUS Medical School, Singapore
• Adjunct Assistant Professor – Lee Kong Chian School of Medicine, Singapore
• Clinical Lecturer – Yong Loo Lin School of Medicine, Singapore
• Service Chief @ NNI TTSH Campus - SingHealth Duke-NUS Memory and Cognitive Disorder Centre
• Faculty Member - SingHealth DUKE-NUS Artificial Intelligence in Medicine Institute (AIMI)
• Associate Member - SingHealth Innovation Committee
• Board Member, Chapter of Neurologists, Academy of Medicine, Singapore

• SingHealth GCEO Outstanding Researcher Award - 2025
• Singapore Health Quality Service Award, Star - 2024
• Singapore Health Quality Service Award, Gold - 2023
• NMRC Research Training Fellowship Award - 2021
• NNI Quality Service Award, Star - 2021

• Ng, K.P.*, Chong, J.S.X.*, Lussier, F., Therriault, J., Rahmouni, N., Savard, M., Stevenson, J., Pascoal, T., Gauthier, S., Rosa-Neto, P. and Zhou, J.H., 2026. Functional network phenotypes of mild behavioural impairment: cognitive effects moderated by amyloid. Alzheimer's Research & Therapy. *contributed equally
• Liu, G., Yu, T., Ebrahimkhani, S., Shawn, L.Z.Z., Ng, K.P.* and Cheung, N.M.*, How Do Medical MLLMs Fail? A Study on Visual Grounding in Medical Images. In The Fourteenth International Conference on Learning Representations. *joint corresponding author
• Ng, K.P.*, Shen, J.Y.*, Chiew, H.J., Ng, A.S.L., Kandiah, N., Rosa-Neto, P. and Gauthier, S., 2023. White Matter Hyperintensity as a Vascular Contribution to the AT (N) Framework. The Journal of Prevention of Alzheimer's Disease, pp.1-14. *contributed equally
• Ng, K.P.*, Qian, X.*, Ng, K.K., Ji, F., Rosa-Neto, P., Gauthier, S., Kandiah, N., Zhou, J.H. and Alzheimer's Disease Neuroimaging Initiative, 2022. Stage-dependent differential influence of metabolic and structural networks on memory across Alzheimer’s disease continuum. Elife, 11, p.e77745. *contributed equally
• Ng, K.P.*, Chiew, H.J.*, Rosa-Neto, P., Kandiah, N., Ismail, Z. and Gauthier, S., 2021. Associations of AT (N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals. Translational neurodegeneration, 10(1), pp.1-14 *contributed equally
• Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., Chan, Y.H., Jiang, L., Therriault, J., Benedet, A.L., Shin, M., Kandiah, N., Greenwood, C.M. and Rosa-Neto, P., 2021. Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease. Translational Neurodegeneration, 10(1), pp.1-11.
• Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., et al. 2017. Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology, 88(19), pp.1814-1821.
• Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., Therriault, J., Kang, M.S., Shin, M., Guiot, M.C., Guo, Q., Harada, R., Comley, R.A. and Massarweh, G., 2017. Monoamine oxidase B inhibitor, selegiline, reduces 18 F-THK5351 uptake in the human brain. Alzheimer's Research & Therapy, 9(1), p.25.